American College of Clinical Pharmacy
      Search      Cart


NIH Releases New Version of COVID-19 Treatment Guidelines

October 10, 2023

The COVID-19 Treatment Guidelines Panel (the Panel) has published an update to the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Important changes include:

  • The Panel added 2 new sections, Abatacept and Infliximab, to discuss the available clinical data on the use of these agents to treat certain hospitalized patients with COVID-19.
  • Therapeutic Management of Hospitalized Adults With COVID-19 provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat COVID-19 in certain hospitalized adults.
  • The Panel has updated the recommendation for use of Metformin in nonhospitalized patients with COVID-19. There is currently insufficient evidence to recommend either for or against the use of metformin in these patients. The Panel also added information about a secondary endpoint from the COVID-OUT study to the text and clinical data table.
  • In the section on Antithrombotic Therapy in Patients With COVID-19, the Panel revised the recommendation on the use of an intermediate dose of anticoagulation for venous thromboembolism prophylaxis in hospitalized patients with COVID-19 who require intensive care unit-level care. This change is based on results from the recently published ANTICOVID trial.
  • Minor updates were made to several other Guidelines sections, including Ritonavir-Boosted Nirmatrelvir (Paxlovid), Special Considerations in People Who Are Immunocompromised, and Influenza and COVID-19.

For a full list of updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.